Compugen (CGEN) Reiterated at Buy by Stifel After Overview of COM701 Trial

October 6, 2026 7:45 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).The analyst commented, "We’re reiterating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found